Targets › TAAR1
3 programs from 3 companies in 6 trials: 5 Phase 3, 1 Phase 1; Psychiatry; next expected readout Mar 2027.
Intracellular G protein-coupled receptor for trace amines, which recognizes endogenous amine-containing metabolites such as beta-phenylethylamine (beta-PEA), 3-iodothyronamine (T1AM), isoamylamine (IAA), cadaverine (CAD), cyclohexylamine (CHA), p-tyramine (p-TYR), trimethylamine (TMA), octopamine and tryptamine. Also functions as a receptor for various drugs and psychoactive substances, such as amphetamine and…. (UniProt, Q96RJ0)
Open in Phaseline: the race on TAAR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Minerva Neurosciences | Roluperidone (MIN-101) Trace amine-associated receptor 1 (TAAR1) agonist | TAAR1 | Phase 3 | Negative Symptoms of Schizophrenia | Dec 2027 |
| Otsuka | Ulotaront (SEP-363856) Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist | HTR1A, TAAR1 | Phase 3 | Schizophrenia; Generalized Anxiety Disorder | Oct 2028 |
| Newleos Therapeutics | NTX-2001 TAAR1 receptor partial agonist | TAAR1 | Phase 1 | Alcohol Use Disorder | Mar 2027 |
Generalized Anxiety Disorder (3) Schizophrenia (1) Negative Symptoms of Schizophrenia (1) Alcohol Use Disorder (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.